TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03324737

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interactive Smartphone App
Description: There are six main components to the APP.~* Goal Setting: personalizes diet, activity, and weight loss goals for patients based on their starting point.~* Food choices and recommendations: App has an automated and immediate recommendation of foods if the choice selected from food database is not optimal. It has a calorie and nutrients tracker to enable patients to track their food intake.~* Activity and steps tracker: App has a pedometer to count physical activity and steps to enable patients to track their progress towards goals.~* Interactive video lessons: App has video lessons pushed weekly to the patient according to her needs. The videos encompass aspects of diet, lifestyle and behavior management.~* Healthcare Professionals Support: App has a chat channel to enable interaction between participants and healthcare professionals.
Study: NCT01247519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-hospitalization care
Description: Post-hospitalization care included telephone call contact for caring after discharge, for opening for question, and for health education.
Study: NCT03213496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk prescription
Description: 30-40 minutes daily, for five days at the week, all weeks up to surgery.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional care
Description: Patient do not walk before surgery
Study: NCT05512728

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VR
Description: The IVR environment was provided by Shinecon VR (Shinecon, china). Shinecon VR features, have a large field of view and high-quality display; with aspheric lens , lens diameter 40MM, view angle 108 , sharpness 99%, visibility 100%, color .38MM and pupillary distance adjustment 65 MM.~The shinecon VR setup was powered by a HUAWEI Y7 prime phone running the freely available IVR software.~Shinecon VR provides videos for nature, forest, wind, desert and animals. That included noise-cancelling headphones playing background sound from the IVR simulation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: • (titration of 0.05 mg/kg per dose) according to Modified Wilson sedation scale Score to achieve grade 1 (Oriented, eyes may be closed but can respond to 'Can you tell me your name?' 'Can you tell me where you are right now?'
Study: NCT01255943

Intervention type: BEHAVIORAL
Intervention: healthcare staff processes for infection prevention
Description: Toyota lean and positive deviance discovery and action dialogues to facilitate process improvement
Study: NCT01419860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elective colon resection
Description: In our scientific experiment, we evaluate microcirculation in colon wall and anastomosis with laser induced fluorescence videoangiography of ICG. By implementing this technique we can measure average pixel intensity of fluorescence signal in area of interest on bowel, which represents tissue perfusion in this respective part of intestinal wall.
Study: NCT04219722

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Injection of DESIRIAL®
Description: DESIRIAL® is a hyaluronic acid injectable gel intended to treat symptoms associated with vulvovaginal atrophy in postmenopausal women by vaginal mucosa rehydration in this study.~1 mL of DESIRIAL® will be injected in the vestibule and on the posterior and lateral walls of the vagina, 2 to 3 cm after the introitus.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Injection of DESIRIAL®
Description: DESIRIAL® is a hyaluronic acid injectable gel intended to treat symptoms associated with vulvovaginal atrophy in postmenopausal women by vaginal mucosa rehydration in this study.~1 mL of DESIRIAL® will be injected in the vestibule and on the posterior and lateral walls of the vagina, 2 to 3 cm after the introitus.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Injection of placebo
Description: Placebo is an isotonic saline solution (0.9% NaCl).~1 mL of placebo will be injected in the vestibule and on the posterior and lateral walls of the vagina, 2 to 3 cm after the introitus.
Study: NCT02796781

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lung stem cells
Description: Patients will receive clinical grade lung stem cells (LSCs)injected into lung via fiberoptic bronchoscopy.
Study: NCT02774603

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aquatic Locomotor Training
Study: NCT01748617

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Controlled diet
Description: 1 week of controlled diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled diet
Description: 1 week of controlled diet
Study: NCT01056991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: warming mattress
Description: comparison of under patient warming mattress to forced air warming blankets in preventing peri-operative hypothermia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: warming blanket
Study: NCT02774603

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Land Locomotor Training
Study: NCT01783353

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc gluconate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn starch pill
Study: NCT01187329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperinsulinemic normoglycemic clamp (HNC)
Description: Prior to anesthetic induction, a baseline blood glucose value will be obtained, followed by an insulin infusion of 5 mU.Kg-1.min-1. When blood glucose is \<110 mg/dL, a variable continuous infusion of glucose (dextrose 20%) supplemented with potassium (40 mEq/L) and phosphate (30 mmol/L) is administered to preserve normoglycemia (80-110 mg/dL). The glucose infusion is titrated to target glucose levels by checking blood glucose every 5 - 15 min with Accu-Check (Roche Diagnostics, Switzerland) glucose monitor. At sternal closure, insulin infusion is decreased to 1 mU/Kg/min. On admission to the ICU, insulin treatment follows the ICU protocol. The dextrose infusion is slowly weaned off over 2 - 4 hrs maintaining blood glucose \> 80 mg/dL. Arterial blood glucose is measured every 30 - 60 min for 2 hrs, then, as stated in ICU protocol.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: Baseline arterial blood glucose will be obtained before anesthetic induction. Repeat measurements are performed every 30-90 min. Glucose \>150 on CPB will receive insulin according to intraoperative protocol. After surgery, insulin is given according to ICU protocol. Target glucose \< 180 mg/dL.
Study: NCT00671632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon, triazolam, and placebo (56 possible combinations total)
Description: Randomized sequence over eight consecutive days to include the following:~Ramelteon 16 mg, tablets, orally, one day only;~Ramelteon 80 mg, tablets, orally, one day only;~Ramelteon 160 mg, tablets, orally, one day only;~Triazolam 0.25 mg, capsules, orally, one day only;~Triazolam 0.50 mg, capsules, orally, one day only;~Triazolam 0.75 mg, capsules, orally, one day only;~Ramelteon placebo-matching tablets, orally, one day only, OR Triazolam placebo-matching capsules, orally, one day only;~Additional dose of study medication or placebo, tablets or capsules, orally, one day only.
Study: NCT02267720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occlusal-proximal ART restorations - Ketac Molar
Description: Occlusal-proximal ART restorations - Ketac Molar

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusal-proximal ART restorations - Vitro Molar
Description: Occlusal-proximal ART restorations - Vitro Molar
Study: NCT03115749

Intervention type: OTHER
Group type: OTHER
Intervention: Intestinal biopsies during colonoscopy
Description: Intestinal biopsies during colonoscopy

Intervention type: OTHER
Group type: OTHER
Intervention: Intestinal biopsies during colonoscopy
Description: Intestinal biopsies during colonoscopy

Intervention type: OTHER
Group type: OTHER
Intervention: Intestinal biopsies during colonoscopy
Description: Intestinal biopsies during colonoscopy

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsies taken on surgical specimen
Description: biopsies taken on surgical specimen after intestinal resection

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsies taken on surgical specimen
Description: biopsies taken on surgical specimen after intestinal resection

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsies taken on surgical specimen
Description: biopsies taken on surgical specimen after intestinal resection
Study: NCT03961113

Intervention type: OTHER
Intervention: Assessment by questionnaire
Description: At diagnosis a gerontological evaluation will be carried out including the following tests: ADL, iADL, MNA, SF 36, SPPB, FRIED criteria and GDS. The set of scales and scores of the procedure is commonly used in geriatrics to assess the fragility of the patient.~A monthly telephone reassessment conducted by an ARC will collect ADL and iADL from the first month to the eleventh month. The end-of-study consultation will be conducted by a geriatrician at the 12th month and will include the following tests: ADL, iADL, MNA, SF 36, the SPPB, the criteria of FRIED and the GDS
Study: NCT02854358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mixed powder of A. digitata and M. sylvestris
Study: NCT02973477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin is a sodium glucose transporter-2 (SGLT-2) inhibitor, a new class of glucose lowering agent that reduces hyperglycemia in patients with T2D by reducing renal glucose reabsorption.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin is a sodium glucose transporter-2 (SGLT-2) inhibitor, a new class of glucose lowering agent that reduces hyperglycemia in patients with T2D by reducing renal glucose reabsorption.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Glimepiride is a sulfonylurea agent that reduces hyperglycemia in patients with T2D by stimulating insulin release from the pancreatic beta cells and reduction of glucose output from the liver.
Study: NCT00504725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Interventional

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: placebo
Study: NCT02726438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1450
Description: Debio 1450, 40 mg, powder for oral solution, for reconstitution in 5% dextrose in water.
Study: NCT02062944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: SRL minimization will be performed if clinically, biochemically and histologically stable. Patients entering the minimization phases will be reduced every month by 50% of total dose of Sirolimus until they reach .5mg daily for one month. Then .5 mg every other day, then twice weekly, the once weekly dosing. This should take approximately 6 month to complete minimization. Liver function tests will be monitored every 2 weeks. For any patient developing liver dysfunction, liver biopsy will be performed. Patients will then be completely withdrawn and followed post-withdrawal for 12 months.
Study: NCT04490642

Intervention type: OTHER
Intervention: Questionnaire
Description: Final version Childhood Bladder and Bowel Dysfunction for 5-12 years old questionnaire in Korean language to patients who never encountered beforehand in other available languages (Dutch, English).

Intervention type: OTHER
Intervention: Questionnaire
Description: Final version Childhood Bladder and Bowel Dysfunction for 5-12 years old questionnaire in Korean language to patients who never encountered beforehand in other available languages (Dutch, English).
Study: NCT00979589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: The first group will receive a 300mg loading dose (LD) of clopidogrel on the day of randomization, followed by 75 mg clopidogrel/day from Day 2 to 3 months. ASA will be given in a total dose ranging between 75 mg and 300 mg (open label) on the first day, followed by blinded 75 mg once /day from Day 2 to Day 21st. Between Day 21st and 3-month visits, ASA 75 mg will be replaced by a placebo of ASA 75 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of clopidogrel and Asprin
Description: The second group will receive open label ASA in a total dose ranging between 75 mg and 300 mg on the first day, followed by blinded 75 mg once /day from Day 2 to 3 months. A placebo for clopidogrel will be given from the day of randomization until the 3-month visit.
Study: NCT04001894

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90mg
Description: Ticagrelor (90.0 mg twice daily) for 2 weeks, followed by a 2-week washout period then 2 weeks crossover phase of clopidogrel (75mg once daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg
Description: Ticagrelor (90.0 mg twice daily) for 2 weeks, followed by a 2-week washout period then 2 weeks crossover phase of clopidogrel (75mg once daily).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75mg
Description: Clopidogrel (75mg once daily) for 2 weeks, followed by a 2-week washout period then 2 weeks crossover phase of ticagrelor (90.0 mg twice daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75mg
Description: Clopidogrel (75mg once daily) for 2 weeks, followed by a 2-week washout period then 2 weeks crossover phase of ticagrelor (90.0 mg twice daily).
Study: NCT03048695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GMT
Description: Metacognitive strategy training where the primary objective is to stop ongoing behavior to define goal hierarchies and monitor performance
Study: NCT01318590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUS procedure with drug injection
Description: EUS procedure with injection of 10 ml Bupivacaine 0.5% and 40 mg of Triamcinolone in the celiac plexus after administration of intravenous (IV) antibioprophylaxis

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: EUS procedure
Description: EUS procedure without any drug injection
Study: NCT00670293

Intervention type: RADIATION
Intervention: Positron Emission Tomography (PET) using [11C]raclopride
Description: Participants with AN will undergo three PET scans at two separate time points. The first scan will occur when participants are underweight (but not less than 75% ideal body weight), and the second and third scans will occur 2 to 4 weeks after participants have accomplished weight restoration. Healthy participants will have two PET scans at a single timepoint.

Intervention type: RADIATION
Intervention: Positron Emission Tomography (PET) using [11C]raclopride
Description: Participants with AN will undergo three PET scans at two separate time points. The first scan will occur when participants are underweight (but not less than 75% ideal body weight), and the second and third scans will occur 2 to 4 weeks after participants have accomplished weight restoration. Healthy participants will have two PET scans at a single timepoint.

Intervention type: DRUG
Intervention: Methylphenidate
Description: The second PET scan for healthy participants and third PET scan for participants with AN will be performed after administration of 60 mg of methylphenidate, a psychostimulant that allows for accumulation of dopamine (DA) extraneuronally.

Intervention type: DRUG
Intervention: Methylphenidate
Description: The second PET scan for healthy participants and third PET scan for participants with AN will be performed after administration of 60 mg of methylphenidate, a psychostimulant that allows for accumulation of dopamine (DA) extraneuronally.

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI) scan
Description: Participants with AN will undergo two MRI scans, and healthy participants will undergo one MRI scan. The scans will be conducted in conjunction with the PET scans.

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI) scan
Description: Participants with AN will undergo two MRI scans, and healthy participants will undergo one MRI scan. The scans will be conducted in conjunction with the PET scans.
Study: NCT03780465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral idronoxil suspension
Description: Idronoxil powder up to 150 ml ORA-BLEND® flavoured syrup

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66 (A)
Description: Idronoxil formulated in suppository base A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66 (A)
Description: Idronoxil formulated in suppository base A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66 (B)
Description: Idronoxil formulated in suppository base B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66 (B)
Description: Idronoxil formulated in suppository base B
Study: NCT00735137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal pessary (CE0482, MED/CERT ISO 9003 / EN 46003)
Description: Inserted from randomization till 36-37 weeks of gestation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal pessary (CE0482, MED/CERT ISO 9003 / EN 46003)
Description: Inserted from randomization till 36-37 weeks of gestation
Study: NCT01317797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: namilumab (MT203)
Description: administered three times, subcutaneous in the abdomen
Study: NCT02854358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypozalix spray (artificial saliva)
Description: Hypozalix spray (artificial saliva)
Study: NCT02973477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Glimepiride is a sulfonylurea agent that reduces hyperglycemia in patients with T2D by stimulating insulin release from the pancreatic beta cells and reduction of glucose output from the liver.
Study: NCT03967990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined cornmeal flour
Description: 48 g/d of refined cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
Study: NCT03967990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined cornmeal flour
Description: 48 g/d of refined cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined cornmeal flour
Description: 48 g/d of refined cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
Study: NCT01317797

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered three times, subcutaneous in the abdomen
Study: NCT00419601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanyl
Description: Start dose:9 µg/kg/h Maximum dose: 30 µg/kg/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: start dose: 3 µg/kg/h Maximum dose: 10 µg/kg/h
Study: NCT01470651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: 50mg - 250mg pills, taken each morning, for 14 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Inactive pill, matched to look like active medication
Study: NCT03830788

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation by brachytherapy
Description: Brachytherapy by Iodine 125 delivering 144 Gy to the prostate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation by SBRT
Description: SBRT delivers 7.25 Gy per fraction, in five fractions, corresponding to a total dose of 36.25 Gy to the prostate. Fiducials are implanted in the prostate.
Study: NCT02571283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocktail
Description: Administered as a single dose injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocktail
Description: Administered as a single dose injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Administered 20 minutes+ before additional medications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Administered 20 minutes+ before additional medications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marcaine
Description: Administered 20 minutes or more after Exparel is administered.
Study: NCT02657759

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CARDICHOL

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Study: NCT03967990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined cornmeal flour
Description: 48 g/d of refined cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined cornmeal flour
Description: 48 g/d of refined cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50/50 refined cornmeal-bran mix
Description: 48 g/d of a mix of 50% refined cornmeal flour and 50% corn bran flour served to participants as two daily 24 g servings via pita breads and/or muffins

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50/50 refined cornmeal-bran mix
Description: 48 g/d of a mix of 50% refined cornmeal flour and 50% corn bran flour served to participants as two daily 24 g servings via pita breads and/or muffins

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50/50 refined cornmeal-bran mix
Description: 48 g/d of a mix of 50% refined cornmeal flour and 50% corn bran flour served to participants as two daily 24 g servings via pita breads and/or muffins

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50/50 refined cornmeal-bran mix
Description: 48 g/d of a mix of 50% refined cornmeal flour and 50% corn bran flour served to participants as two daily 24 g servings via pita breads and/or muffins
Study: NCT00209222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: antibody